Author

J. Allegretti

h-index 46 View on Semantic Scholar

We have 3 of 400 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Nov 2026

Colonoscopy-based Clostridioides difficile screening for inflammatory bowel disease patients.

Patients with IBD have an increased risk for Clostridioides difficile infection, and the significance of asymptomatic colonization is poorly understood. Overlapping symptoms often complicate diagnosis, and there is a lack of validated screening methods. Colonic wash aspirates collected during routine colonoscopies may...

J. Allegretti, Alexander D. Carlin, E. McClure et al. · Gut microbes · 0 citations

Review Open access Oct 2026

Identification and Characterization of Patient Populations at High Risk for Clostridioides difficile Infection (CDI): A Narrative Review

Clostridioides difficile infection (CDI) is a major cause of infections worldwide and can lead to life-threatening complications and a severe impact on patients’ quality of life (QoL). CDI can affect anyone, but it is generally accepted that those at greatest risk include people receiving antibiotics, of older age, and...

J. Allegretti, E. Dubberke, C. Ferreira et al. · Infectious Disease and Thera... · 0 citations

Open access Oct 2026

Long-term Benefits of Mirikizumab on Patient-Reported Outcomes in Individuals with Crohn's Disease: 2-Year Results from the VIVID-2 Extension Study.

BACKGROUND Mirikizumab, an anti-IL-23p19 monoclonal antibody, has demonstrated clinical efficacy in Crohn's disease (CD), improving symptoms and quality of life (QoL) over one year in the VIVID-1 trial. This analysis from the VIVID-2 open-label extension evaluated its long-term impact on CD symptoms and QoL at two year...

Min-Hu Chen, Ailsa L. Hart, A. Vadhariya et al. · Clinical and Translational G... · 0 citations